Skip to main content

Table 11 Concomitant medication use by adjudicated AOE and serious AOE status

From: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

 

Total (n = 449)

No AOE (n = 371)

Any AOE (n = 78)

Serious AOE (n = 74)

Baseline concomitant medications

 Antihypertensives

86 (19)

63 (17)

23 (29)

22 (30)

 Acetylsalicylic acid

39 (9)

23 (6)

16 (21)

15 (20)

 Platelet aggregation inhibitors

38 (8)

22 (6)

16 (21)

15 (20)

 Anti-diabetic agents

24 (5)

13 (4)

11 (14)

10 (14)

 Lipid-modifying agents

22 (5)

16 (4)

6 (8)

6 (8)

 Anticoagulants

15 (3)

13 (4)

2 (3)

2 (3)

Concomitant medication use at any time

 Antihypertensives

233 (52)

181 (49)

52 (67)

50 (68)

 Acetylsalicylic acid

125 (28)

92 (25)

33 (42)

33 (45)

 Platelet aggregation inhibitors

122 (27)

85 (23)

37 (47)

37 (50)

 Anticoagulants

58 (13)

50 (13)

8 (10)

8 (11)

 Lipid-modifying agents

51(11)

39 (11)

12 (15)

12 (16)

 Anti-diabetic agents

45 (10)

26 (7)

19 (24)

18 (24)

  1. Data are no. (%) of patients
  2. AOE arterial occlusive event